<DOC>
	<DOCNO>NCT01511822</DOCNO>
	<brief_summary>Polycystic ovary syndrome ( PCOS ) heterogeneous syndrome variety metabolic endocrine abnormality clinical symptom . The primary defect PCOS consist abnormal androgen synthesis secretion , particularly ovarian theca cell . Insulin resistance obesity may act trigger , explain frequent association PCOS metabolic condition . Hyperinsulinaemia , result insulin resistance , stimulate ovarian adrenal androgen secretion suppress sex hormone-binding globulin synthesis liver . It result increase free , biologically active androgen related clinical sign hirsutism , acne , seborrhea , alopecia . Combined oral contraceptive ( COC ) therapy common treatment PCOS widely use group patient provide clinical improvement area excessive hair growth , unpredictable menses , acne , weight gain . More recent study outline deficiency myo-inositol woman PCOS insulin-resistance . Myo-inositol precursor many inositol-containing compound play critical diverse role signal transduction , membrane biogenesis , vesicle trafficking , chromatin remodeling . It precursor synthesis phosphatidylinositol polyphosphate ( PIPs ) source several second messenger . It report administration myo-inositol reduces serum insulin , decrease serum testosterone enhances ovulation . Due different beneficial action , aim present study evaluate clinical , metabolic endocrine effect treatment COC ( drospirenone ethinyl estradiol ) alone combination myo-inositol , young woman PCOS insulin resistance .</brief_summary>
	<brief_title>Clinical , Metabolic Endocrine Effects Treatment With Drospirenone Ethinyl Estradiol Alone Combination With Myo-inositol Young Women With Polycystic Ovary Syndrome ( PCOS ) Insulin Resistance</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Women fulfil two three diagnostic criterion PCOS , accord 2003 Rotterdam Consensus conference Women PCOS , insulin resistance , acne , hirsutism seborrhea Women preexist secondary endocrine disorder Women wish conceive next 12 month Women contradiction oral contraceptive use Women personal history hypertension , diabetes mellitus cardiovascular disorder Women receive treatment oral contraceptive , drug previous 6 month enter study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>PCOS</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Hyperandrogenism</keyword>
	<keyword>Myo-inositol</keyword>
</DOC>